

## Hemady<sup>™</sup> (dexamethasone) – New orphan drug approval

- On October 3, 2019, the FDA approved Dexcel Pharma's <u>Hemady (dexamethasone)</u> 20 mg tablets, in combination with other antimyeloma products for the treatment of adults with multiple myeloma.
- Dexamethasone is available in a variety of different formulations for oral, injection, topical, and ophthalmic administration. Dexamethasone is generically available as an oral tablet and elixir.
  - The generic tablet is available in 0.5 mg. 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg and 6 mg strengths.
  - The generic tablets and elixir are approved for allergic states, dermatologic diseases, endocrine disorders, gastrointestinal diseases, hematologic disorders, neoplastic diseases, nervous system diseases, ophthalmic disease, renal diseases, respiratory diseases, rheumatic disorders, and some miscellaneous diseases.
- Hemady is contraindicated in patients with systemic fungal infections and hypersensitivity to dexamethasone.
- Warnings and precautions of Hemady include alterations in endocrine function, immunosuppression
  and increased risk of infections, alterations in cardiovascular/renal function, venous and arterial
  thromboembolism, vaccination, ophthalmic effects, gastrointestinal perforation, osteoporosis,
  myopathy, behavioral and mood disturbances, Kaposi's sarcoma, Hemady in combination with antimyeloma products, and embryo-fetal toxicity.
- The most common adverse reactions with Hemady use were cardiovascular, dermatologic, endocrine, fluid and electrolyte disturbances, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, ophthalmic, abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, and weight gain.
- The recommended dose of Hemady is 20 mg or 40 mg orally once daily on specific days depending
  on the treatment regimen. Refer to the prescribing information of the other anti-myeloma products
  used in combination with Hemady for specific Hemady dosing.
- Dexcel Pharma's launch plans for Hemady are pending. Hemady will be available as a 20 mg tablet.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.